ISABELLA CASTRILLON: Open Payments
NPI 1952054074 · JUPITER, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$852 in 17 payments from 11 companies in 2025. Trend: 2023 $601 · 2024 $497 · 2025 $852
Food & beverage: $852
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $206 |
| Ardelyx, Inc. | 1 | $161 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Madrigal Pharmaceuticals | 1 | $102 |
| Aimmune Therapeutics, Inc. | 3 | $80 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $38 |
| Phathom Pharmaceuticals, Inc. | 1 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Janssen Biotech, Inc. | 1 | $28 |
| Novo Nordisk Inc | 1 | $27 |
Products named: IBSRELA, GIVLAARI, REZDIFFRA, ZENPEP, XIFAXAN, VOQUEZNA, TERLIVAZ, TREMFYA.
Industry payments across FL — which companies pay providers there.
